Show simple item record

dc.contributor.authorBurza, Sakiben_GB
dc.contributor.authorSinha, Prabhat Ken_GB
dc.contributor.authorMahajan, Ramanen_GB
dc.contributor.authorLima, María Angelesen_GB
dc.contributor.authorMitra, Gauraben_GB
dc.contributor.authorVerma, Neenaen_GB
dc.contributor.authorBalsegaram, Manicaen_GB
dc.contributor.authorDas, Pradeepen_GB
dc.date.accessioned2014-01-20T21:25:18Z
dc.date.available2014-01-20T21:25:18Z
dc.date.issued2014-01
dc.identifier.citationRisk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients Following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India. 2014, 8 (1):e2536 PLoS Negl Trop Disen_GB
dc.identifier.issn1935-2735
dc.identifier.pmid24392166
dc.identifier.doi10.1371/journal.pntd.0002536
dc.identifier.urihttp://hdl.handle.net/10144/311644
dc.description.abstractA proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse; however, the risk factors for relapse are not well understood. With the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) implemented a program in Bihar, India, using intravenous liposomal amphotericin B (Ambisome) as a first-line treatment for VL. The aim of this study was to identify risk factors for VL relapse by examining the characteristics of immunocompetent patients who relapsed following this regimen.
dc.language.isoenen
dc.publisherPublic Library of Scienceen_GB
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen_GB
dc.subjectKala Azar/Visceral Leishmaniasisen_GB
dc.subjectHIV/AIDSen_GB
dc.titleRisk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, Indiaen
dc.identifier.journalPLoS Neglected Tropical Diseasesen_GB
refterms.dateFOA2019-03-04T11:02:56Z
html.description.abstractA proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse; however, the risk factors for relapse are not well understood. With the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) implemented a program in Bihar, India, using intravenous liposomal amphotericin B (Ambisome) as a first-line treatment for VL. The aim of this study was to identify risk factors for VL relapse by examining the characteristics of immunocompetent patients who relapsed following this regimen.


Files in this item

Thumbnail
Name:
Burza et al-2014-Risk Factors ...
Size:
475.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record